Alzheimer’s Early Detection Act of 2026
To amend title XXVII of the Public Health Service Act and title XIX of the Social Security Act to require coverage of Alzheimer's biomarker testing under group health plans, group and individual health insurance coverage, and the Medicaid program.
This bill proposes to make Alzheimer's biomarker testing mandatory for coverage under group health plans, individual health insurance, and the Medicaid program. Biomarker tests can help in the early detection of Alzheimer's disease, potentially improving treatment outcomes. The bill aims to ensure that all eligible individuals have access to this critical diagnostic tool, regardless of their health insurance type or economic status.
The bill would affect millions of Americans, particularly those with group health plans and those enrolled in Medicaid. It would provide more people with the opportunity to receive early Alzheimer's diagnoses, enabling them to access treatments and plan for future care more effectively.
HB9823 was introduced on July 22, 2026, and referred to the House Committee on Energy and Commerce. The bill is currently in its initial stage of review and discussion. It has the potential to significantly impact the healthcare landscape by mandating coverage for a vital diagnostic test, but it still has several steps ahead in the legislative process.
